Key Takeaways EW sees strong global uptake in surgical tech and TAVR, with Q1 TAVR sales topping $1 billion again. Edwards' TMTT sales rose 58% in Q1, driven by PASCAL and EVOQUE system adoption across the U.S. and Europe. Macro volatility and foreign exchange headwinds are pressuring EW's operating margin and sales growth.Edwards Lifesciences (EW) is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform is positioned fo ...

Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight manufactures and sells light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [2]. Financial Performance - The company previously reported strong sales for LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [4]. - A further revenue forecast cut on July 8, 2025, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [5].

Core Insights - Abbott Laboratories, a healthcare giant based in Illinois, has experienced a strong stock performance since the beginning of the year, contrasting with its peers in the industry [1]. Group 1 - The stock of Abbott Laboratories (NYSE: ABT) has been on a fine run from the start of the year until yesterday [1].

Core Insights - Inspira Technologies has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price requirements, confirming the closing bid price was at or above $1.00 per share for 10 consecutive business days [1][2] Company Developments - The CEO of Inspira Technologies, Dagi Ben-Noon, highlighted that the compliance milestone reflects growing market confidence in the company's strategic direction, emphasizing a transformative shift marked by securing a large commercial order and establishing a government partnership for national adoption and global scaling [3] - Recent achievements include the clinical integration of the ART100 system in Tier-1 U.S. hospitals, expansion of manufacturing capabilities, and a significant $22.5 million purchase order, which are seen as catalysts for ongoing discussions with commercial and governmental entities worldwide [3] Product and Technology Focus - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its INSPIRA™ ART100 system cleared by the U.S. FDA for cardiopulmonary bypass and ECMO procedures [4] - The company is also developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake, and advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [4] - With multiple cleared products and a growing intellectual property portfolio, Inspira Technologies is positioned as an attractive player in the life-support and MedTech landscape, aligning with industry trends such as consolidation and strategic partnerships [4]

Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Eye Spear Market (By Product Type, Segment, Application, End-User, Sales Channel, Regional Analysis), Company Profiles, Eye Spear Product Details, Pictures, Recent Developments and Market Dynamics - Global Forecast (2025 - 2032)" report has been added to ResearchAndMarkets.com's offering. The global eye spear market is projected to reach US$ 265.6 Million by 2032, from US$ 162.7 Million in 2024. The application of eye spears extends across a range of surgical ...

Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Tumor Ablation Market (By Technology, Treatment Mode, Application, End-User, Regional Analysis), Company Profiles, Product Portfolio, Recent Developments, Key Trends and Market Dynamics - Global Forecast (2025 - 2032)" report has been added to ResearchAndMarkets.com's offering. The global tumor ablation market is expected to reach US$ 4.15 billion by 2032, from US$ 1.67 billion in 2024. Technological advancements to enhance accuracy, portability, and cost-effe ...

Financial Performance & Guidance - Abbott Labs initially delivered high single-digit sales growth and 11% EPS growth, exceeding expectations, with gross margin expansion of 100 basis points [5] - Management tightened full-year earnings guidance and ticked down organic sales growth forecast and operating margin outlook, leading to investor disappointment [1] - The company maintains its 2026 guidance for high single-digit growth and double-digit EPS [8] - Diagnostics business recovery in China is delayed from Q2 to Q4, impacting revenue growth guidance [7] - COVID forecast was brought down, resulting in a 50-60 basis point drop in revenue growth [14] Business Segment Performance - Medical devices experienced strong organic growth of 122%, with double-digit growth in cardiovascular, diabetes, and neuromodulation businesses [16] - Electrophysiology and structural heart businesses showed acceleration and double-digit growth, respectively, while the heart failure business grew 14% [17] - Pharmaceutical business grew at a high single-digit rate of 8% in emerging markets [17] Strategic Actions & Outlook - Abbott has a $445 billion revenue business growing at 75% to 8% with double-digit EPS and margin expansion [7] - The company has a $7 billion buyback authorization and believes the stock's reaction is an overreaction [21] - Management is actively addressing the diagnostic business issues, including management changes and frequent meetings with the diagnostic team [11]

Financial Performance - The company delivered high single-digit sales growth [2] - EPS (Earnings Per Share) grew by 11%, exceeding expectations [2] - Gross margin expanded by 100 basis points (1%) [2] - The company maintains its 2026 guidance for high single-digit growth and double-digit EPS [5] Business Operations & Challenges - Diagnostics business experienced a setback due to a slower-than-expected recovery in China [3][4] - Revenue guidance for the diagnostics business was adjusted, delaying the China recovery from Q2 to Q4 [4] - Other regions showed recovery in the diagnostics business: United States grew 7%, Europe grew 8%, Latin America grew 16% [3] - The company is a $44.5 billion revenue business growing 7.5% to 8% [5] Market Outlook - Analysts have largely maintained their price targets and forecasts, suggesting the issue is an overreaction [5] - The fundamentals of the company's business remain intact despite the diagnostics challenges [5]

Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was extreme."I think this is a little bit of an overreaction. Of course, we are all over this," Ford said. "We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact, and this is just really a point in time that we have to get through."While Abbott posted a top and bottom line beat for t ...

Key Takeaways ISRG received FDA clearance for its Vessel Sealer Curved, expanding its da Vinci surgical instrument lineup. ISRG's new tool performs four functions in one, improving control and efficiency in tight anatomical spaces. ISRG enhanced the design with better visibility and versatility, plus clearance to transect lymphatic vessels.Intuitive Surgical (ISRG) recently received FDA clearance for its Vessel Sealer Curved, a multifunctional instrument designed for use with compatible da Vinci surgical ...